Get the Stockscreener App
120.73
0.34%
-0.41
Pre-market:
120.85
0.12
+0.10%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $120.73, with a volume of 12.54M.
It is down -0.34% in the last 24 hours and down -3.76% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$121.14
Open:
$121.71
24h Volume:
12.54M
Relative Volume:
1.99
Market Cap:
$209.93B
Revenue:
$43.84B
Net Income/Loss:
$13.90B
P/E Ratio:
15.14
EPS:
7.9725
Net Cash Flow:
$6.92B
1W Performance:
-3.42%
1M Performance:
-3.76%
6M Performance:
-2.97%
1Y Performance:
+3.37%
1-Day Range:
$120.33
$122.49
1-Week Range:
$120.25
$124.42
52-Week Range:
$113.50
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
120.73 | 210.65B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
SYK
Stryker Corp
|
362.94 | 137.52B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
BSX
Boston Scientific Corp
|
91.71 | 135.25B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
MDT
Medtronic Plc
|
100.29 | 126.41B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
85.14 | 48.43B | 5.88B | 1.34B | 799.60M | 2.3489 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Top Wall Street Forecasters Revamp Abbott Expectations Ahead Of Q4 Earnings - Benzinga
Procter & Gamble, Abbott Laboratories And 3 Stocks To Watch Heading Into Thursday - Benzinga
Abbott (ABT) stock price ticks higher as heart-device news lands ahead of earnings — what investors watch - TechStock²
Oral Antibiotics Market Overview and Leading Players: Abbott - openPR.com
Abbott Laboratories Stock: Defensive Giant Or Sleeping Growth Story? - AD HOC NEWS
ABT.SW Abbott (SIX) CHF100.00 intraday: earnings 22 Jan 2026 could shift outlook - Meyka
Oncology Nutrition Market Overview and Leading Players: Abbott - openPR.com
Carrier Screening Market with Insights from Abbott - openPR.com
Abbott Laboratories (ABT) Q4 Earnings Preview: What to Expect - GuruFocus
Is Abbott Laboratories (ABT) Pricing Reflect Its Medical Device And Diagnostics Momentum? - simplywall.st
Abbott Laboratories Q4 2025 Earnings Preview (ABT:NYSE) - Seeking Alpha
Abbott works with AtaCor Medical on extravascular ICD system - cardiovascularbusiness.com
Abbott secures CE mark for Tactiflex dual ablation catheter - Medical Device Network
Abbott Laboratories (ABT) Q4 Earnings Report Preview: What To Look For - Finviz
Abbott Laboratories (ABT) Q4 earnings report preview: What to look for - MSN
What Should You Anticipate From Abbott Laboratories (ABT) Q4 Earnings - Bitget
Lab on Chip Market Set for Dynamic Development with Key Players - openPR.com
What To Expect From Abbott Laboratories’s (ABT) Q4 Earnings - The Globe and Mail
What To Expect From Abbott Laboratories's (ABT) Q4 Earnings - Finviz
Abbott's Tactiflex gains CE mark - BioWorld MedTech
Abbott secures key approval for new catheter capable of PFA, radiofrequency ablation - cardiovascularbusiness.com
The Bull Case For Abbott Laboratories (ABT) Could Change Following Dividend Hike And New AFib Device Approval - Yahoo Finance
Abbott gets Europe’s CE mark for dual ablation catheter - MedTech Dive
2 Healthcare Names That Could Get a Big Boost From Earnings - Finviz
Abbott Labs stock rating reiterated at Buy by TD Cowen ahead of Q4 report - Investing.com
Abbott (ABT) Gains European Approval for Innovative Ablation Cat - GuruFocus
Abbott picks up CE mark for TactiFlex dual-energy ablation catheter - MassDevice
New heart catheter lets EU doctors switch energy types mid-AFib procedure - Stock Titan
Turtle Creek Wealth Advisors LLC Has $5.17 Million Position in Abbott Laboratories $ABT - MarketBeat
Week Ahead: Trade War Risks Are Back—and Markets Are Pricing Them In - Investing.com
Mizuho downgrades Exact Sciences stock to Neutral on Abbott acquisition - Investing.com
Abbott Laboratories: Sustained Double-Digit Growth Momentum and Strategic Expansion Support Buy Rating - TipRanks
Abbott stock price watch: ABT heads into earnings week with Libre sensor recall on the radar - TechStock²
ABT.SW Abbott Laboratories (SIX) at CHF100.00 pre-earnings: watch 22 Jan for guidance - Meyka
Abbott Laboratories $ABT Shares Purchased by Wealth Enhancement Advisory Services LLC - MarketBeat
Will Robust Adult Nutrition Business Performance Fuel ABT's Q4 Earnings? - TradingView — Track All Markets
Abbott Laboratories: Q4 Earnings On The Horizon (NYSE:ABT) - Seeking Alpha
Allstate Corp Grows Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Genflow names new chairman as gene therapy group looks to next phase - Proactive Investors
Abbott stock drops, ABT traders eye earnings after MLK Day shuts Wall Street - TechStock²
Abbott Laboratories: Who is the newcomer to Pōkeno? - BusinessDesk | NZ
Massachusetts Financial Services Co. MA Acquires 821,325 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories (ABT) positioned to benefit as healthcare sector enters recovery phase - MSN
Abbott Laboratories (ABT) Positioned to Benefit as Healthcare Sector Enters Recovery Phase - Yahoo Finance
Abbott Laboratories (NYSE:ABT) Stands Out as a Dependable Dividend Stock for Income Investors - Chartmill
Is Abbott Laboratories (ABT) Price Weakness Creating A Potential Opportunity Now? - Yahoo Finance
Abbott (ABT) Declines More Than Market: Some Information for Investors - Yahoo Finance Singapore
Options Corner: Abbott Laboratories Offer Economic Insulation Ahead Of Earnings - Benzinga
FDA confirms recalls for Abbott CGM sensors—new lawsuit alleges company concealed information - cardiovascularbusiness.com
Insights Into Abbott (ABT) Q4: Wall Street Projections for Key Metrics - Yahoo Finance
TorHoerman Law Announces $495 Million Jury Verdict in Case Involving Abbott Laboratories - ACCESS Newswire
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):